We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Web Portal Offers Fast Search of Trial Data

By Biotechdaily staff writers
Posted on 27 Mar 2006
A new website has been launched that is designed to increase the transparency of industry-sponsored clinical trials of new medicines by providing a faster and more-precise search, available in five languages.

The portal was developed by the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA, Geneva, Switzerland) in cooperation with IBM Corp. More...
(White Plains, NY, USA). This is the first Internet search engine constructed to link to online information about ongoing and completed clinical trials sponsored by researched-based pharmaceutical companies worldwide. Users can search for clinical trial information in German, French, Japanese, and Spanish, as well as English. Depending on the pattern of use, additional languages may be added later.

"Furthermore,” announced Dr. Harvey E. Bale, director general of the IFPMA, "since many people are unfamiliar with medical expressions, we have improved the search facility so that it suggests synonyms for medical conditions and helps to correct misspelled words, including the names of medicines.” The extended reach now allows a search for trials corresponding both to the term entered by a layperson and the term's synonyms. According to Dr. Bale, multiple criteria searches are now easier as are searches by geographical area. "In this way, anyone can program the search engine to look for trials which are underway in the area where you live, in the disease that interests you.”

The amount of clinical trial information accessible via the IFPMA portal has increased from 26,000 pages to more than 88,000 pages, and this number continues to climb. The number of linking sites has also increased, from 10 to 15. These linking sites include pharmaceutical company sites, pharmaceutical industry association resources, and U.S. governmental sites, such as the U.S. Library of Medicine. Other resources, such as the European Union's planned Europharm facility, will be linked as soon as they become available.

The IFPMA is a global nonprofit non-governmental organization representing research-based pharmaceutical, biotechnology, and vaccine companies and national industry associations in developed and developing countries.



Related Links:
IFPMA

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
hCG Whole Blood Pregnancy Test
VEDALAB hCG-CHECK-1
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.